These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 18984744)

  • 1. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.
    Martin B; Golden E; Carlson OD; Pistell P; Zhou J; Kim W; Frank BP; Thomas S; Chadwick WA; Greig NH; Bates GP; Sathasivam K; Bernier M; Maudsley S; Mattson MP; Egan JM
    Diabetes; 2009 Feb; 58(2):318-28. PubMed ID: 18984744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression.
    Andreassen OA; Dedeoglu A; Stanojevic V; Hughes DB; Browne SE; Leech CA; Ferrante RJ; Habener JF; Beal MF; Thomas MK
    Neurobiol Dis; 2002 Dec; 11(3):410-24. PubMed ID: 12586550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI; Petit GH; Ranganathan S; Li JY; Oliveira CR; Brundin P; Björkqvist M; Rego AC
    Exp Neurol; 2011 Oct; 231(2):314-9. PubMed ID: 21763311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.
    Alpaugh M; Masnata M; de Rus Jacquet A; Lepinay E; Denis HL; Saint-Pierre M; Davies P; Planel E; Cicchetti F
    Mol Ther; 2022 Apr; 30(4):1500-1522. PubMed ID: 35051614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
    Yang S; Chang R; Yang H; Zhao T; Hong Y; Kong HE; Sun X; Qin Z; Jin P; Li S; Li XJ
    J Clin Invest; 2017 Jun; 127(7):2719-2724. PubMed ID: 28628038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.
    Duarte AI; Sjögren M; Santos MS; Oliveira CR; Moreira PI; Björkqvist M
    Sci Rep; 2018 Jun; 8(1):8961. PubMed ID: 29895889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.
    Ona VO; Li M; Vonsattel JP; Andrews LJ; Khan SQ; Chung WM; Frey AS; Menon AS; Li XJ; Stieg PE; Yuan J; Penney JB; Young AB; Cha JH; Friedlander RM
    Nature; 1999 May; 399(6733):263-7. PubMed ID: 10353249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
    Blázquez C; Chiarlone A; Sagredo O; Aguado T; Pazos MR; Resel E; Palazuelos J; Julien B; Salazar M; Börner C; Benito C; Carrasco C; Diez-Zaera M; Paoletti P; Díaz-Hernández M; Ruiz C; Sendtner M; Lucas JJ; de Yébenes JG; Marsicano G; Monory K; Lutz B; Romero J; Alberch J; Ginés S; Kraus J; Fernández-Ruiz J; Galve-Roperh I; Guzmán M
    Brain; 2011 Jan; 134(Pt 1):119-36. PubMed ID: 20929960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy.
    Martin B; Chadwick W; Cong WN; Pantaleo N; Daimon CM; Golden EJ; Becker KG; Wood WH; Carlson OD; Egan JM; Maudsley S
    J Biol Chem; 2012 Sep; 287(38):31766-82. PubMed ID: 22822065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington's disease.
    Sjögren M; Duarte AI; McCourt AC; Shcherbina L; Wierup N; Björkqvist M
    Sci Rep; 2017 Oct; 7(1):13896. PubMed ID: 29066728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
    Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y
    J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic reversal of Huntington's disease by in vivo self-assembled siRNAs.
    Zhang L; Wu T; Shan Y; Li G; Ni X; Chen X; Hu X; Lin L; Li Y; Guan Y; Gao J; Chen D; Zhang Y; Pei Z; Chen X
    Brain; 2021 Dec; 144(11):3421-3435. PubMed ID: 34918046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of huntington's disease.
    Li E; Choi J; Sim HR; Kim J; Jun JH; Kyung J; Ha N; Kim S; Ryu KH; Chung SS; Kim HS; Lee S; Seol W; Song J
    BMB Rep; 2023 Mar; 56(2):178-183. PubMed ID: 36593104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
    Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
    Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.
    Nithianantharajah J; Hannan AJ
    Neuroscience; 2013 Oct; 251():66-74. PubMed ID: 22633949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Metabolic Study of Huntington's Disease.
    Nambron R; Silajdžić E; Kalliolia E; Ottolenghi C; Hindmarsh P; Hill NR; Costelloe SJ; Martin NG; Positano V; Watt HC; Frost C; Björkqvist M; Warner TT
    PLoS One; 2016; 11(1):e0146480. PubMed ID: 26744893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease.
    Zeng Y; Guo W; Xu G; Wang Q; Feng L; Long S; Liang F; Huang Y; Lu X; Li S; Zhou J; Burgunder JM; Pang J; Pei Z
    Drug Des Devel Ther; 2016; 10():1443-51. PubMed ID: 27110099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice.
    Molnár MF; Török R; Szalárdy L; Sümegi E; Vécsei L; Klivényi P
    Acta Neurobiol Exp (Wars); 2016; 76(3):176-81. PubMed ID: 27685770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice.
    Duan W; Guo Z; Jiang H; Ware M; Li XJ; Mattson MP
    Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2911-6. PubMed ID: 12589027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.